These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

41 related articles for article (PubMed ID: 19372863)

  • 1. Treatment interruption for convenience, cost cutting and toxicity sparing.
    Nüesch R; Hirschel B
    Curr Opin HIV AIDS; 2007 Jan; 2(1):31-8. PubMed ID: 19372863
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Virological rebound and its consequences during treatment interruption.
    van Lunzen J; Hoffmann C
    Curr Opin HIV AIDS; 2007 Jan; 2(1):1-5. PubMed ID: 19372858
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment interruption strategies: how great are the risks?
    Paton NI
    Curr Opin Infect Dis; 2008 Feb; 21(1):25-30. PubMed ID: 18192782
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of selecting resistance mutations during treatment interruption.
    Martinez-Picado J; Wai Yan Tam L
    Curr Opin HIV AIDS; 2007 Jan; 2(1):6-13. PubMed ID: 19372859
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment interruption in advanced failing patients.
    Staszewski S
    Curr Opin HIV AIDS; 2007 Jan; 2(1):39-45. PubMed ID: 19372864
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment interruption as a tool to measure changes in immunologic response to HIV-1.
    Kutzler MA; Jacobson JM
    Curr Opin HIV AIDS; 2008 Mar; 3(2):131-5. PubMed ID: 19372954
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stopping HAART temporarily in the absence of virus rebound: exploring new HIV treatment options.
    Lori F; Foli A; Lisziewicz J
    Curr Opin HIV AIDS; 2007 Jan; 2(1):14-20. PubMed ID: 19372860
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monitoring clinical trials of therapeutic vaccines in HIV infection: role of treatment interruption.
    Lederman MM; Penn-Nicholson A; Stone SF; Sieg SF; Rodriguez B
    Curr Opin HIV AIDS; 2007 Jan; 2(1):56-61. PubMed ID: 19372866
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment interruption in chronic HIV-1 infection: does it deliver?
    Willberg CB; Nixon DF
    Curr Opin HIV AIDS; 2007 Jan; 2(1):26-30. PubMed ID: 19372862
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Partial treatment interruptions.
    Deeks SG; Martin JN
    Curr Opin HIV AIDS; 2007 Jan; 2(1):46-55. PubMed ID: 19372865
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early antiretroviral therapy: the role of cohorts.
    Sabin CA
    Curr Opin HIV AIDS; 2009 May; 4(3):200-5. PubMed ID: 19532051
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of CKBM-A01, a Chinese herbal medicine, among asymptomatic HIV patients.
    Maek-a-nantawat W; Phonrat B; Dhitavat J; Naksrisook S; Muanaum R; Ngamdee V; Pitisuttithum P
    Southeast Asian J Trop Med Public Health; 2009 May; 40(3):494-501. PubMed ID: 19842434
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atherosclerotic vascular disease in HIV: it is not just antiretroviral therapy that hurts the heart!
    van Leuven SI; Sankatsing RR; Vermeulen JN; Kastelein JJ; Reiss P; Stroes ES
    Curr Opin HIV AIDS; 2007 Jul; 2(4):324-31. PubMed ID: 19372907
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Issues in the design of trials comparing management strategies for heavily pretreated patients.
    Phillips AN; Cohen C; Lundgren JD
    Curr Opin HIV AIDS; 2006 Nov; 1(6):476-81. PubMed ID: 19372849
    [TBL] [Abstract][Full Text] [Related]  

  • 15. General 4-week toxicity study with EMS in the rat.
    Pfister T; Eichinger-Chapelon A
    Toxicol Lett; 2009 Nov; 190(3):271-85. PubMed ID: 19442710
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Can treatment interruption strategies improve the management of HIV infection ?].
    Izopet J
    Virologie (Montrouge); 2006 Jun; 10(3):207-217. PubMed ID: 34679308
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Resistance profiles after different periods of exposure to a first-line antiretroviral regimen in a Cameroonian cohort of HIV type-1-infected patients.
    Soria A; Porten K; Fampou-Toundji JC; Galli L; Mougnutou R; Buard V; Kfutwah A; Vessière A; Rousset D; Teck R; Calmy A; Ciaffi L; Lazzarin A; Gianotti N
    Antivir Ther; 2009; 14(3):339-47. PubMed ID: 19474468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment interruption in children with HIV infection.
    Green H; Gibb DM
    Curr Opin HIV AIDS; 2007 Jan; 2(1):62-8. PubMed ID: 19372867
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interleukin-2 before antiretroviral therapy in patients with HIV infection: a randomized trial (ANRS 119).
    Molina JM; Levy Y; Fournier I; Hamonic S; Bentata M; Beck-Wirth G; Gougeon ML; Venet A; Madelaine I; Sereni D; Jeanblanc F; Boulet T; Simon F; Aboulker JP;
    J Infect Dis; 2009 Jul; 200(2):206-15. PubMed ID: 19508157
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Erratum to: Biological evaluation of the toxicity and the cell cycle interruption by some benzimidazole derivatives.
    Błaszczak-Świątkiewicz K; Sikora J; Szymański J; Danilewicz M; Mikiciuk-Olasik E
    Tumour Biol; 2016 Jun; 37(6):8467-8468. PubMed ID: 27039917
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.